Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Promising BioNTech data on triple negative breast cancer treatment
Health and Wellness

Promising BioNTech data on triple negative breast cancer treatment

Last updated: December 15, 2024 8:21 am
Share
Promising BioNTech data on triple negative breast cancer treatment
SHARE

Researchers may have discovered a promising candidate for the next generation of immunotherapy drugs in the form of bispecific antibodies targeting two key proteins in cancer – PD1 or PD-L1 and VEGF. A recent small early trial presented at the San Antonio Breast Cancer Symposium by researchers working with BioNTech showcased positive results in patients with triple negative breast cancer using a bispecific compound called BNT-327. This compound, if further trials prove successful, could become a crucial part of treating not only triple negative breast cancer but potentially other types of cancer as well.

The development of bispecific antibodies targeting PD1 or PD-L1 and VEGF builds upon the groundbreaking discovery of checkpoint inhibitors in the 1990s. These inhibitors, such as Merck’s Keytruda, have revolutionized cancer treatment by stimulating the immune system to recognize and eliminate cancer cells. However, there is still room for improvement in this area. BioNTech co-founder and CMO Ă–zlem TĂĽreci believes that PD-L1 or PD1 and anti-VEGF bispecifics represent the next generation of checkpoint inhibitors that could further enhance cancer treatment.

The potential of bispecific antibodies targeting these proteins gained attention when Summit Therapeutics released data showing that their PD1 and VEGF bispecific antibody outperformed Keytruda in a Phase 3 trial for advanced lung cancer. While experts noted the impressive results, they also cautioned that further research is needed to determine if the drug can extend overall survival, a critical measure in oncology research.

This article highlights the significant progress being made in the field of immunotherapy and the potential impact of bispecific antibodies targeting PD1 or PD-L1 and VEGF. As researchers continue to explore and develop new treatments, the future of cancer therapy looks promising.

See also  STAT Morning Rounds: Screen time and autism
TAGGED:BioNTechbreastcancerDatanegativepromisingTreatmenttriple
Share This Article
Twitter Email Copy Link Print
Previous Article Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal
Next Article The sun may spit out giant solar flares more often than we thought The sun may spit out giant solar flares more often than we thought
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Serial bank robber told cops he needed money to buy Christmas gifts, FBI says

Davell Luster, a 55-year-old man, has been charged with robbing three banks in Chicago this…

December 23, 2024

The Milky Way’s black hole may be spinning at top speed

An image of Sagittarius A*, the black hole at the centre of the Milky Way…

June 16, 2025

Anthropic co-founder Jared Kaplan is coming to JS Sessions: AI

About Jared Kaplan’s session Jared Kaplan, co-founder and Chief Science Officer of Anthropic, will be…

May 12, 2025

Patient care declines after private equity buys hospitals, study finds

Health policy experts at Beth Israel Deaconess Medical Center (BIDMC) recently published a paper in…

January 11, 2025

Having a Bad Day? Here Are 21 Things You Can Do to Turn It Around

“To affect the quality of the day, that is the highest of arts.”Henry David Thoreau…

October 9, 2024

You Might Also Like

In a First, Pig Liver Helped a Cancer Patient Survive for More Than a Month
Tech and Science

In a First, Pig Liver Helped a Cancer Patient Survive for More Than a Month

October 10, 2025
Presidential Message on National Breast Cancer Awareness Month
The White House

Presidential Message on National Breast Cancer Awareness Month

October 10, 2025
STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown
Health and Wellness

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown

October 10, 2025
Former Red Sox Star Mike Greenwell Dead At 62 After Cancer Battle
Entertainment

Former Red Sox Star Mike Greenwell Dead At 62 After Cancer Battle

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?